# Paul Bresge

> Paul Bresge is co-founder and CEO of Ray Therapeutics, a former CEO of jCyte and an outside director of Healios. His career spans manufacturing operations, courier services, industrial tools and startup leadership. He helped conclude jCyte’s 2020 Santen licensing agreement, worth up to $252 million, and leads Ray following its $100 million Series A in 2023 and $125 million Series B in 2026.

- **Role:** Co-Founder and Chief Executive Officer at Ray Therapeutics
- **Organizations:** Ray Therapeutics, jCyte, Healios K.K., Blizzard Courier Service Ltd., Industrial Tool Company (ITC), Pharmasol, Winning Pitch Challenge
- **Education:** Bachelor of Arts (BA), York University
- **Known for:** Helped conclude jCyte’s May 2020 licensing agreement with Santen, valued at up to $252 million plus royalties; terms included $50 million upfront, a $12 million convertible note and up to $190 million in potential milestones., Co-founded Ray Therapeutics in 2021., Led Ray as it announced a $100 million Series A in May 2023 and a $125 million Series B in April 2026.

## Career timeline

- **1988-05** — Became Director of Operations at Pharmasol.
- **1992-04** — Became Executive Vice-President at Blizzard.
- **1998-08** — Became Chairman of ITC.
- **2003-03** — Became President and CEO of Blizzard.
- **2011-02** — Became jCyte Advisory Board Chair and Acting CEO.
- **2016-08** — Became CEO of jCyte.
- **2020-05** — jCyte announced its Santen licensing agreement, valued at up to $252 million.
- **2021-02** — Co-founded Ray Therapeutics; became Co-Founder and CEO in June 2021.
- **2022** — Became an outside director of Healios.
- **2023-05** — Ray announced a $100 million Series A led by Novo Holdings.
- **2026-04** — Ray announced a $125 million Series B led by Janus Henderson Investors.

## Achievements

- Helped conclude jCyte’s May 2020 licensing agreement with Santen, valued at up to $252 million plus royalties; terms included $50 million upfront, a $12 million convertible note and up to $190 million in potential milestones.
- Co-founded Ray Therapeutics in 2021.
- Led Ray as it announced a $100 million Series A in May 2023 and a $125 million Series B in April 2026.
- Became an outside director of Healios in 2022.
- Serves as a Winning Pitch Challenge mentor.

## Latest updates

- **2026-09** — Ray announced an $8 million CIRM grant; Bresge publicly thanked CIRM for its continued partnership.
- **2026-05** — Ray appointed Vikas Sinha as a director and audit committee chair; Bresge welcomed his financial and strategic experience.
- **2026-04** — Ray closed a $125 million Series B led by Janus Henderson Investors, with new and existing investors participating.

## Links

- Website: https://raytherapeutics.com/
- LinkedIn: https://www.linkedin.com/in/paulbresge/

---

Profile page: https://yespress.io/paul-bresge
Published by YesPress — https://yespress.io
Last updated: 2026-10-25